Collateral for a security interest recorded Jun 13, 2025 (JPMorgan Chase Bank, N.A.).
Term ends Jun 4, 2030 · High confidence
20-year base term ends Jun 4, 2030
Held by Solta Medical, Inc.
Filed Jun 4, 2010 as application 12/794,611 · Granted May 24, 2011
Base term, 20 years from filing
Today
2010
2030
Clock starts
Jun 4, 2010
Jun 4, 2010
Term ends
Jun 4, 2030
Jun 4, 2030
Granted
May 24, 2011
May 24, 2011
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 4, 2010, when this application, 12/794,611, was filed | Jun 4, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 4, 2030 | High confidence |
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jun 16, 2010 Reel 24546, frame 28 | Bockenstedt, Craig R.; Crunkilton, Jeffrey R.; Wing, Gregory T.; Bennett, Frederick J.; Little, Blake W. | Medicis Technologies Corporation | Assignment of Assignor's Interest |
| Feb 6, 2013 Reel 29768, frame 734 | Medicis Technologies Corporation | Liposonix, Inc. | Change of Name |
| Apr 3, 2013 Reel 30147, frame 642 | Liposonix, Inc. | Silicon Valley Bank | Security Agreement |
| Apr 18, 2013 Reel 30249, frame 268 | Liposonix, Inc. | Silicon Valley Bank | Security Interest - Mezzanine Loan |
| Nov 19, 2013 Reel 31674, frame 454 | Liposonix, Inc. | Capital Royalty Partners II L.P.; Capital Royalty Partners II - Parallel Fund "a" L.P.; Parallel Investment Opportunities Partners II L.P. | Short-Form Patent Security Agreement |
| Nov 19, 2013 reel/frame not recorded | Liposonix, Inc. | Capital Royalty Partners II L.P. | Short-Form Patent Security Agreement |
| Nov 19, 2013 reel/frame not recorded | Liposonix, Inc. | Capital Royalty Partners II - Parallel Fund "a" L.P. | Short-Form Patent Security Agreement |
| Nov 19, 2013 reel/frame not recorded | Liposonix, Inc. | Parallel Investment Opportunities Partners II L.P. | Short-Form Patent Security Agreement |
| Jan 24, 2014 Reel 32126, frame 370 | Capital Royalty Partners II L.P.; Capital Royalty Partners II - Parallel Fund "a" L.P.; Parallel Investment Opportunities Partners II L.P. | Liposonix, Inc. | Release of Security Interest in Patents |
| Jan 24, 2014 Reel 32126, frame 531 | Silicon Valley Bank | Liposonix, Inc. | Release of Security Interest in Patents |
| Mar 11, 2019 Reel 48556, frame 758 | Bausch Health Americas, Inc.; Bausch & Lomb Incorporated; Bausch Health US, LLC; Solta Medical, Inc.; Medicis Pharmaceutical Corporation; Salix Pharmaceuticals, Inc.; Salix Pharmaceuticals, Ltd.; Santarus, Inc.; Orapharma, Inc.; Precision Dermatology, Inc. | The Bank of New York Mellon, as Notes Collateral Agent | Security Interest |
| May 13, 2021 Reel 56227, frame 174 | Aesthera; Liposonix, Inc. | Solta Medical, Inc. | Merger |
| Jun 8, 2021 Reel 56811, frame 814 | Bausch & Lomb Incorporated; Bausch Health US, LLC; Solta Medical, Inc.; Medicis Pharmaceutical Corporation; Salix Pharmaceuticals, Inc.; Salix Pharmaceuticals, Ltd.; Santarus, Inc.; Orapharma, Inc.; Precision Dermatology, Inc.; Bausch Health Americas, Inc. | The Bank of New York Mellon, as Notes Collateral Agent | Security Interest |
| Feb 10, 2022 Reel 59121, frame 1 | Bausch & Lomb Incorporated; Bausch Health US, LLC; Solta Medical, Inc.; Medicis Pharmaceutical Corporation; Salix Pharmaceuticals, Inc.; Salix Pharmaceuticals, Ltd.; Santarus, Inc.; Orapharma, Inc.; Precision Dermatology, Inc.; Bausch Health Americas, Inc. | The Bank of New York Mellon | Security Agreement |
| Jun 13, 2022 Reel 60346, frame 705 | Bausch Health Companies Inc.; Bausch Health, Canada Inc.; Bausch Health Ireland Limited; Solta Medical Ireland Limited | The Bank of New York Mellon | Security Interest |
| Oct 4, 2022 Reel 61595, frame 66 | Bausch Health US, LLC; Bausch Health Americas, Inc.; Medicis Pharmaceutical Corporation; Orapharma, Inc.; Precision Dermatology, Inc.; Salix Pharmaceuticals, Inc.; Salix Pharmaceuticals, Ltd.; Santarus, Inc.; Solta Medical, Inc. | The Bank of New York Mellon, as Notes Collateral Agent | Security Agreement (First Lien) |
| Oct 5, 2022 Reel 61606, frame 468 | Bausch Health US, LLC; Bausch Health Americas, Inc.; Medicis Pharmaceutical Corporation; Orapharma, Inc.; Precision Dermatology, Inc.; Salix Pharmaceuticals, Inc.; Salix Pharmaceuticals, Ltd.; Santarus, Inc.; Solta Medical, Inc. | The Bank of New York Mellon, as Notes Collateral Agent | Security Agreement (Second Lien) |
| Jun 13, 2025 Reel 71564, frame 463 | Medicis Pharmaceutical Corporation; Orapharma, Inc.; Bausch Health US, LLC (F/K/A Valeant Pharmaceuticals North America LLC); Precision Dermatology, Inc.; Salix Pharmaceuticals, Inc.; Santarus, Inc.; Bausch Health Americas, Inc.; Solta Medical, Inc. | The Bank of New York Mellon | U.S. Patent Security Agreement |
| Jun 13, 2025 Reel 71566, frame 200 | Medicis Pharmaceutical Corporation; Orapharma, Inc.; Bausch Health US, LLC (F/K/A Valeant Pharmaceuticals North America LLC); Precision Dermatology, Inc.; Salix Pharmaceuticals, Inc.; Santarus, Inc.; Bausch Health Americas, Inc.; Solta Medical, Inc. | Jpmorgan Chase Bank, N.a. | U.S. Patent Security Agreement |
| Nov 20, 2025 Reel 73654, frame 242 | The Bank of New York Mellon, as Notes Collateral Agent | Bausch & Lomb Incorporated; Bausch Health US, LLC; Solta Medical, Inc.; Medicis Pharmaceutical Corporation; Salix Pharmaceuticals, Inc.; Salix Pharmaceuticals, Ltd.; Santarus, Inc.; Orapharma, Inc.; Precision Dermatology, Inc.; Bausch Health Americas, Inc. | Release of Security Interest |
| Nov 20, 2025 Reel 73654, frame 300 | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Companies Inc.; Bausch Health, Canada Inc.; Bausch Health Ireland Limited; Solta Medical Ireland Limited | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Americas, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch & Lomb Incorporated | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health US, LLC | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Solta Medical, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Medicis Pharmaceutical Corporation | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Salix Pharmaceuticals, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Salix Pharmaceuticals, Ltd. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Santarus, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Orapharma, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Precision Dermatology, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Companies Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health, Canada Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Ireland Limited | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Solta Medical Ireland Limited | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jun 2030
Term ends Jun 4, 2030. No further fees fall due before then
Citations
10
later US patents cite this one
That is above the median of utility patents granted in 2011 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.